SLC1A5 and pancreatic neoplasm: To further illustrate that SLC1A5 correlates with the uptake of Asn by PSCs to promote activation, we treated pancreatic cancer mice with PBS or V9302, respectively, and immunohistochemical staining of their tumors showed that both SLC1A5 and α‐SMA were attenuated in the V9302‐treated group (Figure S3K, Supporting Information).